BioFIT 2018 conference programme is tailored to fit the expectations of its audience, whose sharp minds evolve in the fast-paced and dynamic Life Sciences sector. Built around 12 sessions, 2 workshops and 1 plenary session, the 2018 programme is rooted in three custom-made tracks, addressing the right funding sources for early-stage innovation, best practices in academia-industry R&D collaborations, and nurturing early-stage assets.
BioFIT 2018 features a constantly renewed conference programme, with 3 tracks to match the interests of every player in the sector.
Academia-industry R&D collaborations, early-stage funding sources, and licensing early-stage assets are 2018 guiding principle.
Discover BioFIT 2018 preliminary conference programme:
Globalisation of seed investment can be seen as traditionally geographically anchored, now early-stage investors tend to invest in more diversified areas. Where does the money come from? How far is this evolution towards more global funds going? How fast is it going in the investment community? Will it make the investors more risk taking, will it change the risk landscape? Isn’t there today an ill-balance between the geographical origin of the investment capacities and the areas where projects needing equity investment are teeming?
Companies are now using machine learning in highly specific ways to streamline and improve the many day-to-day biomedical research tasks. The use of AI shifted from generalist tasks to purpose-built tools with numerous applications to speed-up drug discovery at all the different research stages. The panel will address some uses of AI, ultimately cutting R&D costs through the possibility to aggregate and synthesise information, repurpose existing drugs, generate and validate novel drug candidates, design drugs and preclinical experiments…
We will review potential partnerships that are prime examples of the synergies that exist between human and animal health drug development for the benefit of all the patients. Some of these research collaborations leading to forthcoming licensing agreements, there is a strong belief that the product development synergies between human and animal health are key to meet the unique challenges in both markets.
Further than sharing physical means, this session focuses on deliberate strategies of life sciences players and the academic world to pool R&D resources to address common questions and reach common goals through shared R&D strategies and aligned incentives. We will review some duets which chose to take a leap forward and jointly do science that they can’t do on their own.
What are the consequences and benefits of adding patient organisations to existing alliances? How do these collaborations work? How do they create value for the whole life sciences community? What is the actual influence for patients on public/private partnerships? What is the actual involvement of patient organisation in financing the collaborations?
When addressing the contractual relationships between a university and its spin-off: What are the issues regarding equity, royalties and research income? How do VCs, academic institutions, spin-off management and human resources management of the university interact? What are the main conflicts of interests that can arise from people holding dual positions, in the university and in the start-up?
What are the latest common actions jointly taken by the industry, academic institutions, equity investors and governmental institutions to take the assets the earliest and inject the proper amount of money to drive the projects towards licensing at the right moment and safest stage as possible.
Many universities and countries have created tech transfer financing tools which aim at partly derisking academic-origin assets. Should investors in those financing tools be the least demanding and the most patient to make such tech transfer tools succeed in the long run?
Bringing new therapies to treat rare diseases requires more than scientific innovation. Innovation in business models and incubation financing is critical as the need to find ways to cost effectively develop new medicines becomes increasingly important. Initiatives like collaboration centres and rare disease centres try to take the best of both worlds by implementing multidimensional approaches to address the needs of the rare disease community. In addition to conducting their own research, collaborative models with both pharmaceutical companies, academic institutions, start-ups and patient groups are now put in place.
Prior to engaging a non-dilutive financing strategy, it is essential to recognise that this money is not necessarily “free” and potential company founders should carefully assess the costs, and other pros and cons of each potential funding source. In this session, we will wonder whether non-dilutive financing alternatives create hidden dangers, and what the actual conditions and requirements of the emerging players are at the initial stages of funding.
Decisions taken at the very initial stage have major consequences for the future development of start-ups with major pitfalls to be avoided. Is it crucial to picture the exit strategy as soon as the company is created? The session relies on its panellists’ stories to go over different approaches of IPO and exits for start-ups.
Investment in immunotherapies in 2018 is still attractive and sought for, what is its growth potential after several years of being an investment blockbuster? What have been the 2018 investment successes in immunotherapy? Will immunotherapy disrupt the oncology market? Are we at growth, maturity or saturation stage when talking about investment in immunotherapy?
The seed investment market is composed of actors with really diverse degree of specialisation (from totally agnostic and multi-sectorial to pure players in specific therapeutic indications). Do the most specialised funds attract more generalist ones in the financing rounds? What is the respective importance today in the amount of seed investment of the multi-sectorial funds, the 100% healthcare orientated funds and the pure players in the biotech sector.